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Abstract
Clostridium [Clostridioides] difficile infection (CDI) is one of the leading causes of diarrhea
associated with medical care worldwide, and up to 60% of patients with CDI can develop a
recurrent infection (R-CDI). A multi-species microbiota biofilm model of C. difficile was
designed to evaluate the differences in the production of biofilms, sporulation, susceptibility
to drugs, expression of sporulating (sigH, spo0A), quorum sensing (agrD1, and luxS), and
adhesion-associated (slpA and cwp84) pathway genes between selected C. difficile isolates
from R-CDI and non-recurrent patients (NR-CDI). We obtained 102 C. difficile isolates from
254 patients with confirmed CDI (66 from NR-CDI and 36 from R-CDI). Most of the isolates
were biofilm producers, and most of the strains were ribotype 027 (81.374%, 83/102). Most
C. difficile isolates were producers of biofilm (100/102), and most were strongly adherent.
Sporulation was higher in the R-CDI than in the NR-CDI isolates (p = 0.015). The isolates
from R-CDI patients more frequently demonstrated reduced susceptibility to vancomycin
than isolates of NR-CDI patients (27.78% [10/36] and 9.09% [6/66], respectively, p = 0.013).
The minimum inhibitory concentrations for vancomycin and linezolid against biofilms (BMIC)
were up to 100 times and 20 times higher, respectively, than the corresponding planktonic
MICs. Expression of sigH, spo0A, cwp84, and agrD1 was higher in R-CDI than in NR-CDI
isolates. Most of the C. difficile isolates were producers of biofilms with no correlation with
the ribotype. Sporulation was greater in R-CDI than in NR-CDI isolates in the biofilm model
of C. difficile. The R-CDI isolates more frequently demonstrated reduced susceptibility to
vancomycin and linezolid than the NR-CDI isolates in both planktonic cells and biofilm iso-
lates. A higher expression of sporulating pathway (sigH, spo0A), quorum sensing (agrD1),
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and adhesion-associated (cwp84) genes was found in R-CDI than in NR-CDI isolates. All of
these factors can have effect on the recurrence of the infection.
Introduction
Clostridium [Clostridioides] difficile is one of the leading causes of healthcare-associated diar-
rhea worldwide. Since 2011, cases of C. difficile infection (CDI) have increased in the United
States, with 453,000 infections and 29,000 deaths [1].
An estimated 20–35% of patients with CDI can develop a recurrent infection (R-CDI)
within eight weeks of the first episode, with an incidence of 1,846–37,620 cases/year [2]. The
development of R-CDI has been associated with the germination of spores of the strain that
produced the initial infection in the colon or with the acquisition of a new strain [3–5].
The pathogenicity of chronic and recurrent infections has been associated with the produc-
tion of biofilm in some bacterial species [6], and C. difficile has been shown to produce orga-
nized biofilm communities on abiotic surfaces in vitro [7–9]. Furthermore, C. difficile has shown
to produce biofilms in the presence of other bacteria such as Finegoldia magna in vitro and par-
ticipate in complex gut microbiota biofilms in vitro and during infection in vivo in a mouse
model [10, 11]. Such biofilm formation could protect bacteria from cellular immune responses
associated with toxin production and from antibiotics used for the treatment of CDI [10].
C. difficile spores have been found within the biofilms in a simulated chemostat gut model
[11, 12], suggesting that the accumulation of spores within the biofilm of C. difficile could play
a role in the development of R-CDI [13]. Lower spore germination rates have been reported
in C. difficile biofilms than in vegetative cultures [14, 15], which may affect the persistence of
infection.
The development of biofilms has been associated with the ability of bacteria to resist antimi-
crobial agents because they act as a physical barrier and decrease the effective concentration of
antimicrobials [8, 10]. Indeed, the biofilms of C. difficile have shown 100 times greater resis-
tance to metronidazole and 10 times greater resistance to vancomycin than cells cultured in
liquid media [14].
Several factors have been described to have a key role in the formation of C. difficile biofilm,
such as surface factors like S-layer protein, SlpA (encoded by slpA), the cell wall protein
Cwp84 (encoded by cwp84), and the putative quorum sensing regulator LuxS (encoded by
luxS) [8, 10, 16]. In addition, the master regulator of sporulation, Spo0A, has shown to deter-
mine the biofilm-producing phenotype [7, 14]. Recently, the sigma factor of sporulation, SigH,
and the agr quorum sensing system, have been shown to regulate metabolism and virulence
potential in C. difficile [17–20]. Nevertheless, their contributory role in R-CDI development
remains unknown.
Therefore, the aim of this study was to evaluate the effect of biofilm production in a range
of C. difficile ribotypes, their sporulation, antimicrobial susceptibilities, and expression of
genes involved in sporulation and biofilm formation in isolates from recurrent and non-recur-
rent CDI patients.
Material and methods
Setting
Patients were recruited for this study who were treated at the following two hospitals in
Mexico: The Civil Hospital of Guadalajara, "Fray Antonio Alcalde" a tertiary hospital with
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1000 beds in Guadalajara; and the University Hospital "Dr. Jose´ Eleuterio Gonza´lez," a tertiary
teaching hospital with 500 beds in Monterrey.
Ethics statement
The local ethics committee (Comite´ de E´tica en Investigacio´n del Antiguo Hospital Civil de
Guadalajara “Fray Antonio Alcalde,” Jalisco, Mexico) approved this study with reference num-
ber 047/16. Informed consent was waived by the Ethics Committee because no intervention
was involved and no patients identifying information was included.
Study population, CDI diagnosis, and classification of CDI
Patients with unexplained diarrhea (� 3 unformed stools, Bristol scale 5–7) within 24 h were
included. For the diagnosis of CDI, fecal samples were collected, and C. difficile was investi-
gated by real-time PCR (Cepheid Xpert C. difficile/Epi test, Cepheid, Sunnyvale CA). Patients
were defined with CDI when patients were diarrheal and PCR was positive.
R-CDI was defined by the reappearance of diarrhea associated with CDI within eight weeks
after the completion of antibiotic therapy or the resolution of the initial episode [21]. CDI was
classified as NR-CDI when no new episode occurred within eight weeks. Data collected from
patients with R-CDI and NR-CDI included epidemiological and clinical data, prior antibiotic
therapy, and treatment for CDI. The study was reviewed and approved by the Local Ethics
Committee (Approval: 047/16).
Culture of C. difficile and typing of isolates
Fecal specimens were cultured on C. difficile agar (Neogen Corporation, MI) with cefoxitin (16
mg/L) and incubated in an anaerobic chamber (10% CO2, 10% H2, and 80% N2) at 37˚C for 48
h. Isolates were identified by polymerase chain reaction (PCR) with amplification of the triose
phosphate isomerase (tpi) gene [22] and by matrix-assisted laser desorption ionization time-
of-flight mass spectrometry (MALDI-TOF MS). All isolates were stored at −80˚C. The tcdA,
tcdB, cdtA, and cdtB genes were amplified using a multiplex PCR method [22], and the ribo-
typing-PCR was performed as previously described [23].
Selected isolates were subjected to ribotyping by capillary electrophoresis at the C. difficile
Ribotyping Network Reference Laboratory (CDRN) at Leeds Teaching Hospitals NHS Trust
(Leeds, United Kingdom).
C. difficile biofilm model
The biofilm of C. difficile formation was conducted as reported previously with some modifica-
tions. [7, 24] Briefly, each isolate was cultured in brain heart infusion (BHI) broth supple-
mented with 0.5% yeast extract and 0.1% L-cysteine (BHIS) in 96-well microtiter plates and
incubated in anaerobic conditions at 37˚C for 7 days. The planktonic cells were removed, and
absorbance of planktonic cultures was read at 590 nm using a microtiter plate spectrometer
iMarK (Bio-Rad, Hercules, CA, USA). The biofilm was washed with sterile phosphate-buffered
saline (PBS) (200 μl), fixed with 2% glutaraldehyde, and washed again with PBS. Then, 1%
crystal violet was added and the biofilm was washed six more times with sterile water and de-
stained with 30% acetic acid. The optical density was read at 590 nm. The adherence index
(AI) was calculated, and the isolates were classified as strong adherents (AI> 1.20), moderate
adherents (0.90 < AI <1.20), weak adherents (AI between 0.2 and 0.90) and non-adherents
(AI< 0.2) [25]. The assays were performed in triplicate, and only the results with a variation
coefficient greater than 20% were accepted.
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Microbiota–C. difficile biofilm model
For this study, we designed a biofilm model containing C. difficile and species from the intesti-
nal microbiota (Enterococcus faecalis ATCC 29212, E. faecium, Lactobacillus casei, Lactobacil-
lus rahmnosus, and Lactobacillus acidophilus strains obtained from clinical specimens). Each
strain was cultured in BHIS at 37˚C in an anaerobic chamber for 24–48 h and subsequently
diluted 1:10 in BHIS broth. A 200-μl mixture of microbiota and C. difficile (1:1:1:1:1:1 of each
species) were added to each well of a microtiter plate, and the plates were incubated in an
anaerobic chamber at 37˚C for 7 days. The determination of the biofilm was carried out
according to the biofilm model of C. difficile only.
Strains ATCC BAA-1805 (ribotype 027, strong adherent) and ATCC 9689 (ribotype 001,
weak adherent) were used as controls in the biofilm assays.
Antimicrobial susceptibility testing
Antimicrobial susceptibilities were determined by the agar dilution method in selected isolates
[26]. Antibiotics used to treat CDI infections, as well as those associated with the development
of CDI, were included. The minimum inhibitory concentrations (MICs) were determined
for metronidazole (ICN Biomedical, Costa Mesa, CA), vancomycin, linezolid, ciprofloxacin,
moxifloxacin, erythromycin, clindamycin, rifampicin, and tetracycline (Sigma-Aldrich). The
antimicrobial diluents used and the ranges tested were recommended by the Clinical and Lab-
oratory Standards Institute (CLSI, 2019, M100-S28). An overnight culture in Schaedler broth
(Neogen Corporation) of each isolate was inoculated using a multipoint inoculator (104 col-
ony-forming units (CFU)/spot) on Wilkins-Chalgren agar (Neogen Corporation) [27]. The
ATCC 700057 (ribotype 038) was used as a control strain.
Resistance breakpoints were defined according to the CLSI guidelines as follows: moxiflox-
acin and clindamycin� 8 mg/L, tetracycline� 16 mg/L, metronidazole� 32 mg/L, (CLSI,
2019). The breakpoint for vancomycin was defined according to the European Committee on
Antimicrobial Susceptibility Testing (EUCAST, 2019) as greater than 2 mg/L. For antimicro-
bial agents of which no standard breakpoints to C. difficile have yet to be defined, breakpoints
were considered as follows: erythromycin� 8 mg/L (CLSI, 2013), ciprofloxacin,� 8 mg/L,
[28] linezolid� 16 mg/L [29], and rifampicin� 32 mg/L [30].
Biofilm minimum inhibitory concentration
The BMIC was determined for vancomycin and linezolid. Briefly, the planktonic phase of a
7-day-old biofilm was removed, and the antibiotics were prepared in fresh BHIS. Each concen-
tration (from 512 mg/L to 0.5 mg/L) was aliquoted into microtiter plates (one per concentra-
tion), and 200 μl per well were added. The biofilm was resuspended, and the plates were
incubated at 37˚C for 48 h in anaerobiosis.
The BMIC was defined as the lowest concentration of an antimicrobial that prevents
growth. The ATCC 700057 C. difficile strain (ribotype 038) was used as a control.
Spore count in the biofilm
The 7-day-old biofilm was disrupted with a pipette and resuspended in 100 μl PBS. Serial ten-
fold dilutions (10−1–10−7) were incubated at 65˚C for 20 min to kill the vegetative cells. Both
untreated and heat-treated suspensions were streaked on Clostridium difficile agar (Neogen
Corporation, MI, USA) and incubated at 37˚C for 48 h in anaerobic conditions. Total viable
cells and spore counts were determined as CFU/biofilm.
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Quantitative RT-PCR for spo0A, sigH, slpA, cwp84, agrD1, and luxS
Twenty selected strains (10 from R-CDI patients and 10 from NR-CDI patients) were ana-
lyzed. The biofilms incubated for 48 h were washed twice, then the pellet was resuspended in
DEPC water (200 μl) and treated with lysozyme (10 mg/ml) (Bio-basic, Ontario, Canada) and
proteinase K (Bio-basic). Total RNA was isolated using the Qiagen QIAamp DSP Viral RNA
mini kit (QIAGEN, Hilden, Germany). The quantity and quality of the RNA were assessed
using a NanoDrop spectrophotometer. The relative quantification of the expression of the
RNA transcripts of the spo0A, sigH, slpA, cwp84, agrD1, and luxS genes normalized to 16S
rRNA (rrs) was analyzed using the SuperScript III Platinum One-Step kit (Invitrogen, CA,
USA).
Standard curves were generated using 5-fold dilutions of ATCC 9689 RNA for each gene to
determine the efficiency of the reactions. RNA and diethyl pyrocarbonate (DEPC) water con-
trols were also included. The real-time RT-PCRs were performed in two biological samples in
duplicate; 200 ng RNA and 0.5 μl specific primers at 100 nM (listed on Table 1) in a 25-μL
reaction volume were used. The Smart Cycler real-time PCR system (Cepheid) was used with
cycling conditions as follows: 94˚C for 8 min, then 45 cycles of 94˚C for 30 s; 60˚C for spo0A,
sigH and cwp84; 54˚C for slpA, agrD1 and 30 s for luxS and an extension cycle of 72˚C for 25 s.
Melting curves were determined to assure that only the expected PCR products had been gen-
erated. Relative expression�3 was classified as overexpression. Data were normalized and
analyzed using the method described by Chang et al., and the ATCC 9689 was used as a cali-
brator [31].
Statistical analysis
Reduced susceptibility frequencies from planktonic and biofilm R-CDI cultures were com-
pared with NR-CDI cultures using Pearson’s chi-square test and Fisher’s Exact test.
Differences in relative expression ratios mean of biofilm cultures from R-CDI and NR-CDI
were analyzed using Student’s t-test. Non-parametric data were analyzed using the Mann-
Whitney test and Spearman rank correlation test.
All statistical analysis were performed using the SPSS software package. A p value less than
0.05 was considered to be statistically significant.
Results
Study population
In total, 254 patients with CDI (35.29%, female and 64.70%, male; age range, 15–85) were
confirmed by PCR, with 102 isolates of C. difficile recovered. Patients with R-CDI had more
significant exposure to antibiotics before CDI (p = 0.037) than patients with NR-CDI. Fluoro-
quinolones and vancomycin were more frequently used in patients with NR-CDI than in those
with R-CDI (p = 0.000 and 0.024, respectively). Cephalosporins were more frequently used in
patients with R-CDI than in NR-CDI (p = 0.048) (Table 2).
Culture and ribotyping
Sixty-six isolates (64.70%) of patients with NR-CDI and 36 (35.29%) of patients with R-CDI
were obtained. Most of the isolates were found to be ribotype 027 (83/102, 81.37%). The other
isolates were found to be ribotypes 003 and 002 (3/102, 2.94% each); 001, 014, 078, 220, and
076 (2/102, 1.96% each one); and 353 (1/102, 0.98%) (Table 3). No significant differences in
ribotype distribution between the R-CDI and NR-CDI groups was detected (p = 0.476).
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C. difficile biofilm sporulation
In the C. difficile biofilm model, the majority of C. difficile isolates were producers of biofilm
(100/102), with 80.55% of R-CDI isolates and 90.90% of NR-CDI isolates being strongly adher-
ent. No differences were detected in biofilm production among the isolates of R-CDI and
NR-CDI (AIs geometric mean [GM], 53.87 and 54.06, respectively; p = 0.579).
Sporulation was higher in R-CDI than in NR-CDI isolates (5 log10 CFU/biofilm vs. 3.85
log10 CFU/biofilm; p = 0.015).
C. difficile–microbiota biofilm and sporulation
In the biofilm of C. difficile–microbiota, no difference was detected in biofilm production
among the isolates of R-CDI and NR-CDI (AIs GM, 33.04 and 32.89, respectively; p = 0.677).
Table 1. Primer pairs used to amplify the genes studied by real-time RT-PCR.
Target gene 50primer 30primer Source
rrs GGGAGACTTGAGTGCAGGAG GTGCCTCAGCGTCAGTTACA [43]
spoA CTCAAAGCGCAATAAATCTAGGAGC TTGAGTCTCTTGAACTGGTCTAGG [44]
sigH GTTGGTAGCAAAAGAAAAAAGTTATGAG GTACTCTAGTGCTATTTTATCCCCTTCAC [45]
slpA AATGATAAAGCATTTGTAGTTGGTG TATTGGAGTAGCATCTCCATC [43]
cwp84 TGGGCAACTGGTGGAAAATA TAGTTGCACCTTGTGCCTCA [43]
luxS GTGTACTTGATGGAGTAAAGGGAGA TTCTACATCCCATTGGAGATAAGTC [46]
agrD1 TTTGCTAGCTCATTGGCACTT GATTGCTGATTTCTTTGGGTACTT Primer3 software
https://doi.org/10.1371/journal.pone.0220671.t001
Table 2. Clinical characteristics of patients with R-CDI and NR-CDI.
R-CDI (n = 23) NR-CDI (n = 31) p value
Hospitalization
Length of stay (mean days, range) 29.55 (4–124) 20.86 (4–59) 0.181
Intensive care unit, n (%) 6 (26.09) 10 (32.26) 0.427
Length of stay in ICU (mean days, range) 14.77 (2–48) 12.10 (2–48) 0.460
Prior antibiotics
Any antibiotic, n (%) 30 (96.77) 22 (95.65) 0.675
Length of exposure (mean days, range) 21.48 (1–100) 13.52 (1–52) 0.132
No. of antibiotics (mean) 3.65 2.71 0.037�
Cephalosporins 12 (54.54) 8 (27.59) 0.048�
Clindamycin 18 (81.82) 21 (72.41) 0.329
Macrolides 21 (95.45) 27 (91.10) 0.605
Fluoroquinolones 10 (45.45) 27 (91.10) 0.000�
Vancomycin 9 (40.91) 21 (72.41) 0.024�
Metronidazole 19 (86.36) 25 (86.21) 0.657
Carbapenems 14 (63.64) 17 (58.62) 0.472
CDI treatment
Vancomycin 19 (86.36) 24 (80.00) 0.490
Metronidazole 13 (59.09) 19 (63.33) 0.415
Metronidazole/vancomycin 10 (45.45) 16 (56.33) 0.390
Data are no. (%) of patients, unless otherwise noted.
�Significant difference p value <0.05
https://doi.org/10.1371/journal.pone.0220671.t002
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No significant difference was detected in sporulation between the R-CDI and NR-CDI iso-
lates (6.21 log10 and 5.54 log10 CFU/biofilm, respectively; p = 0.565).
Minimum inhibitory concentrations
Drug susceptibility was evaluated on a selection of 65 isolates (26, R-CDI; 39, NR-CDI), and
more than 70% of the isolates were resistant to ciprofloxacin (�8 mg/L), moxifloxacin (�8
mg/L), erythromycin (�8 mg/L), clindamycin (�8), and rifampin (�32 mg/L). All isolates
were susceptible to tetracycline (�4 mg/L) and metronidazole (�8 mg/L).
The isolates from R-CDI patients showed a greater reduced susceptibility to vancomycin
(>2 mg/L) than the isolates from NR-CDI patients (27.78 and 9.09%, respectively). No other
difference was observed between the R-CDI and NR-CDI isolates (Table 4).
Minimum inhibitory concentrations of the biofilm
In C. difficile biofilm isolates without microbiota, a reduced susceptibility to vancomycin was
observed in 91.0% (101/102) of isolates and to linezolid in 89.21% (91/102) of isolates.
The BMICs were up to 100-fold higher for vancomycin and 20-fold higher for linezolid
than the corresponding MICs. No differences between R-CDI and NR-CDI isolates were
observed (Table 5).
Expression of spo0A, sigH, slpA, cwp84, agrD1, and luxS
The relative expression of spo0A, sigH, cwp84, and agrD1 was higher in R-CDI than in
NR-CDI isolates (Fig 1). Overexpression of spo0A (70%, 7/10), sigH (70%, 7/10), cwp84 (40%,
4/10), and agrD1 (70%, 7/10) was higher in R-CDI than in NR-CDI isolates. No significant dif-
ference was detected in the expression levels of slpA and luxS between R-CDI and NR-CDI iso-
lates (Fig 1).
Discussion
Although some bacterial species that cause recurrent or chronic infections have been studied
for their ability to form biofilms in vivo and in vitro [6], C. difficile biofilms have not been
widely studied. In the present study, we evaluated biofilm formation by C. difficile and detected
that most isolates were biofilm producers (strong adherent), independent of the ribotype or
whether the strains were isolated from R-CDI or NR-CDI patients. These results reflect those
of other previous studies that found no correlation between the ribotype, the strain virulence,
or relapse of infection [16].
The expression of quorum sensing regulators and adhesion-associated factors were deter-
mined from biofilm culture. agrD1 and cwp84 were overexpressed in R-CDI isolates, both of
Table 3. Ribotype distribution between R-CDI and NR-CDI strains.
Genotype PCR-Ribotype (n)
R-CDI (n = 36) tcdA+, tcdB+, tcdC Δ18+, cdtA+/cdtB+ 027 (30)
tcdA+, tcdB+, tcdC Δ18−, cdtA-/cdtB- 003 (1), 001 (1), 076 (1), NT (2)
tcdA+, tcdB+, tcdC Δ18−, cdtA+/cdtB+ 353 (1)
NR-CDI
(n = 66)
tcdA+, tcdB+, tcdC Δ18+, cdtA+/cdtB+ tcdA+,
tcdB+,
027 (53),
tcdA+, tcdB+, tcdC Δ18−, cdtA-/cdtB- 002 (3), 014 (2) 003 (2), 220 (2), 076 (1), NT
(1)
tcdA+, tcdB+, tcdC Δ39+, cdtA+/cdtB+ 078 (2)
https://doi.org/10.1371/journal.pone.0220671.t003
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which were previously shown to regulate colonization, virulence, and relapses in in vivo mod-
els [8, 16, 18–20]. By contrast, luxS and slpA expression was similar in R-CDI and NR-CDI iso-
lates. It would be valuable in the future, to analyze the transcription of toxins A and B
involving isolates overexpressing agrD1 and cwp84 from R-CDI and NR-CDI isolates.
Differences in spore formation in biofilms aged 7–10 days compared to vegetative cultures
have been reported previously, including higher viable counts, higher temperature tolerance,
Table 4. Antimicrobial susceptibility (mg/L) from R-CDI and NR-CDI strains.
Antimicrobial agent R-CDI NR-CDI p value
Ciprofloxacin GM 111.43 61.71
Range 8->128 1->128
MIC90 >128 >128
Resistant (%) 96.15 89.74 0.342
Moxifloxacin GM 18.78 14.22
Range 1–32 1–32
MIC90 32.00 32.00
Resistant (%) 92.31 87.23 0.506
Erythromycin GM 190.21 87.70
Range 1->128 1->128
MIC90 >128 >128
Resistant (%) 81.81 95.23 0.152
Clindamycin GM 150.97 66.75
Range 1->128 0.5->128
MIC90 >128 >128
Resistant (%) 90.48 81.82 0.383
Vancomycin GM 2.16 1.76
Range 1–4 0.25–4
MIC90 4.00 2.00
Resistant (%) 27.78 9.09 0.013�
Metronidazole GM 1.59 1.39
Range 0.25–4 0.25–4
MIC90 4.00 2.00
Resistant (%) 0.00 0.00 NA
Linezolid GM 3.92 4.00
Range 0.5–32 0.03–32
MIC90 16.00 16.00
Resistant (%) 38.89 19.70 0.036�
Rifampin GM 13.55 16.02
Range 0.001->128 0.002->128
MIC90 >128 128.00
Resistant (%) 70.59 79.41 0.484
Tetracycline GM 0.26 0.16
Range 0.06–8 0.06–8
MIC90 4.00 0.13
Resistant (%) 0.00 0.00 NA
Breakpoints were as follows: moxifloxacin and clindamycin�8 mg/L, tetracycline�16 mg/L, metronidazole�32 mg/L according to CLSI (2019); vancomycin >2 mg/L
according to EUCAST (2019), erythromycin�8 mg/L according to CLSI (2013); ciprofloxacin,�8 mg/L [28], linezolid�16 mg/L [29] and rifampicin�32 mg/L [30].
�Significant difference p value <0.05
https://doi.org/10.1371/journal.pone.0220671.t004
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and pleiomorphic biofilm structures (thin, thick exosporium surrounding the spores in the
biofilm) [32, 33]. Further studies to compare germination efficiency with co-germinants in
this biofilm model need to be done. In the present study, we analyzed 7-day old biofilms and
found that sporulation was greater in the R-CDI strains than in the NR-CDI strains. In addi-
tion, sporulation was associated with overexpression of the key regulators of the initial steps of
the sporulation pathway, spo0A and sigH, suggesting their involvement in the overproduction
of spores in the biofilm. According to our results, the production of spores can be associated
with recurrent CDI isolates.
In the present study, a high proportion of resistance was detected against ciprofloxacin,
moxifloxacin, erythromycin, clindamycin, and rifampin, and all isolates were susceptible to
tetracycline and metronidazole. No differences were detected between NR-CDI and R-CDI
strains for these antimicrobial susceptibilities.
Conversely, lower susceptibility to linezolid was observed in R-CDI strains than in NR-CDI
strains, and this result is relevant because linezolid is considered to be a possible drug for treat-
ment with CDI. Interestingly, our study population has no records of exposure to this antimi-
crobial agent in the 12 weeks before the diagnosis of CDI. The cfr gene has been associated
with resistance to linezolid and has been detected in C. difficile with a MIC up to 16 mg/L [34].
Further studies are underway to clarify the molecular mechanisms associated with this drug
resistance.
In our study, the isolates from R-CDI patients showed lower susceptibility to vancomycin
(MIC > 2 mg/L) more frequently than isolates from NR-CDI patients (27.78 and 9.09%,
respectively); and this result is important given the wide use of vancomycin for treatment of
CDI.
High MICs have been reported for moxifloxacin, rifampicin, vancomycin, and clindamycin
in ribotypes 001, 017, 027, 176, 078, and 014 [35, 36]. In the present study, high MICs were
detected for the same antibiotics in addition to ciprofloxacin and erythromycin. Most of the
isolates obtained were ribotype 027. No difference in ribotype was found between the R-CDI
and NR-CDI groups. In our population, 027 strains are associated with higher mortality rates
and greater probability of R-CDI [37].
C. difficile isolates from the present study had high exposure to clindamycin, and this expo-
sure has been associated in prior studies with a high excretion of C. difficile spores [38]. There-
fore, the high use of clindamycin in our clinical setting of Mexico may be associated with the
high sporulation detected.
In a 3-day biofilm model of C. difficile, the susceptibility to vancomycin has been reported,
with BMICs up to 100 times higher than the corresponding planktonic MICs [8, 39, 40]. In the
present study, we confirmed a reduced susceptibility to vancomycin in most strains, with
BMICs up to 100 times higher than MICs. Reduced susceptibility of C. difficile [27, 41] and
Table 5. Distribution of MICs and BMICs between R-CDI and NR-CDI strains.
Vancomycin Linezolid
Range GM Resistant (%) p value Range GM Resistant (%) p value
R-CDI MIC 1.00–4.00 1.88 10/36 (27.78) 0.000 0.50–32.0 3.92 3/36 (8.33) 0.000��
BMIC 2.00–256 109.08 35/36 (97.22) 4.00–256.0 87.34 29/36 (80.55)
NR-CDI MIC 0.25–4.00 1.85 6/66 (9.09) 0.000 0.03–32.0 4.02 13/66 (20.0) 0.000��
BMIC 2.00–256 108.35 66/66 (100) 2.00–256.0 89.63 62/66 (95.38)
Data are mg/L of an antimicrobial agent unless otherwise noted.
��Significant difference p value <0.01
https://doi.org/10.1371/journal.pone.0220671.t005
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BMIC values six times higher than MIC have been reported for metronidazole [14]. Despite
our patients having been treated with metronidazole before the diagnosis of CDI, we did not
find isolates with reduced susceptibility to this antimicrobial agent in either planktonic or bio-
film MIC experiments.
Several risk factors have been described for the development of CDI [42]. In our study,
the consumption of cephalosporins and a greater number of previous antibiotics were risk
Fig 1. Expression levels of spo0A, sigH, cwp84, slpA, agrD1, and luxS transcripts between R-CDI and NR-CDI strains. Relative
mRNA transcripts expression means of spo0A (p = 0.003), sigH (p = 0.007), cwp84 (p = 0.001), slpA (p = 0.066), agrD1 (p = 0.001) and
luxS (p = 0.400) from R-CDI and NR-CDI strains. ��Significant difference p value<0.01.
https://doi.org/10.1371/journal.pone.0220671.g001
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factors for R-CDI. In addition, patients with NR-CDI more frequently used fluoroquinolones
(p = 0.000) and vancomycin (p = 0.024) than those with R-CDI.
The primary limitation of this study was that cultures were not performed on fresh samples.
Instead, they were frozen and stored at −20˚C for up to two years with at least two freeze-thaw
cycles, which could explain the low recovery of C. difficile.
In conclusion, the sporulation and overexpression of sigH, spo0A, and agrD1 were greater
in R-CDI than in NR-CDI isolates. The R-CDI isolates had more reduced susceptibility to van-
comycin and linezolid than the NR-CDI isolates in both planktonic cells and biofilm isolates.
These factors may affect the recurrence of the infection because a greater sporulation in the
protected biofilm may facilitate less spore washout from the gut and a higher likelihood of C.
difficile remaining after CDI therapy has ceased.
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